• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-p53 antibody :: Rabbit p53 Polyclonal Antibody

Scan QR to view Datasheet
Catalog # MBS462096
Unit / Price
  0.1 mg  /  $245 +1 FREE 8GB USB
Testing Data
Product Name

p53, Polyclonal Antibody

Also Known As

Rabbit anti P53 Polyclonal antibody

Product Synonym Names
Rabbit anti-P53; P53; Protein 53; Tumor protein 53
Product Gene Name
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Chromosome Location
Chromosome: 17; NC_000017.10 (7571720..7590863, complement). Location: 17p13.1
3D Structure
ModBase 3D Structure for P04637
Species Reactivity
Human, Rat, Mouse
This antibody recognizes ~53 kDa of humanP53 protein. It also reacts with mouse and rat. The other species are not tested.
The Rabbit IgG is purified by Epitope Affinity Purification.
This affinity purified antibody is supplied in sterile Phosphatebuffered saline (pH7.2) containing antibody stabilizer
Size: 100 ug/200 ul (lot specific)
Antigen Preparation
A synthetic peptide corresponding to the N-terminus of human p53 protein
Positive Control
Brain tissue
Cellular Location
Preparation and Storage
The antibodies are stable for 12 months from date of receipt when stored at -20 degree C to -70 degree C. The antibodies can be stored at 2 degree C -8 degree C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.
Other Notes
Small volumes of anti-p53 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-p53 antibody
P53, also known as protein 53, or tumor suppressor protein 53, plays important roles in cellular response to DNA damage and other genomic aberration. Mutations in the p53 tumor suppressor gene giving rise to mutant p53 proteins are among the most common genetic alterations associated with tumor cells. P53 protein is phosphrylated at multiple sites in vivo and in vitro in response to different stimuli. UV caused DNA damage can induce Ser9, Ser15, Ser20 phosphorylation while ATM, ATR, DNA-PK at Ser15 and Ser37.
Applications Tested/Suitable for anti-p53 antibody
ELISA, Western Blot, Immunohistochemistry
Application Notes for anti-p53 antibody
Western Blot: 0.1-1 ug/ml
ELISA: 0.01-0.1 ug/ml
Immunoprecipitation: 2-5 ug/ml
Immunohistochemistry: 2-5 ug/ml

Testing Data of anti-p53 antibody
anti-p53 antibody Testing Data image
NCBI/Uniprot data below describe general gene information for p53. It may not necessarily be applicable to this product.
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
53 kDa
NCBI Official Full Name
NCBI Official Synonym Full Names
tumor protein p53
NCBI Official Symbol
NCBI Official Synonym Symbols
P53; LFS1; TRP53; FLJ92943
  [Similar Products]
NCBI Protein Information
cellular tumor antigen p53; antigen NY-CO-13; OTTHUMP00000221333; OTTHUMP00000221334; OTTHUMP00000221336; OTTHUMP00000221337; OTTHUMP00000221340; phosphoprotein p53; p53 tumor suppressor; transformation-related protein 53
UniProt Protein Name
Cellular tumor antigen p53
UniProt Synonym Protein Names
Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53
UniProt Gene Name
UniProt Synonym Gene Names
UniProt Entry Name
NCBI Summary for p53
This gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity. [provided by RefSeq]
UniProt Comments for p53
Function: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Ref.37 Ref.53 Ref.58 Ref.61 Ref.75 Ref.86

Cofactor: Binds 1 zinc ion per subunit.

Subunit structure: Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1

By similarity. Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. In vitro, the interaction of TP53 with cancer-associated/HPV (E6) viral proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and P53DINP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity

By similarity. Interacts with ARMC10, BANP, CDKN2AIP and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with FBXO42; leading to ubiquination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A. Interacts with DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Ref.8 Ref.34 Ref.37 Ref.38 Ref.46 Ref.48 Ref.49 Ref.50 Ref.51 Ref.53 Ref.54 Ref.56 Ref.57 Ref.58 Ref.59 Ref.63 Ref.64 Ref.66 Ref.68 Ref.70 Ref.71 Ref.72 Ref.75 Ref.80 Ref.82 Ref.85 Ref.86 Ref.91 Ref.92 Ref.94 Ref.103 Ref.104 Ref.105 Ref.106 Ref.116

Subcellular location: Cytoplasm. Nucleus. Nucleus › PML body. Endoplasmic reticulum. Note: Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2. Ref.9 Ref.34 Ref.37 Ref.43 Ref.53 Ref.61 Ref.63 Ref.70Isoform 1: Nucleus. Cytoplasm. Note: Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4. Ref.9 Ref.34 Ref.37 Ref.43 Ref.53 Ref.61 Ref.63 Ref.70Isoform 2: Nucleus. Cytoplasm. Note: Localized mainly in the nucleus with minor staining in the cytoplasm. Ref.9 Ref.34 Ref.37 Ref.43 Ref.53 Ref.61 Ref.63 Ref.70Isoform 3: Nucleus. Cytoplasm. Note: Localized in the nucleus in most cells but found in the cytoplasm in some cells. Ref.9 Ref.34 Ref.37 Ref.43 Ref.53 Ref.61 Ref.63 Ref.70Isoform 4: Nucleus. Cytoplasm. Note: Predominantly nuclear but translocates to the cytoplasm following cell stress. Ref.9 Ref.34 Ref.37 Ref.43 Ref.53 Ref.61 Ref.63 Ref.70Isoform 7: Nucleus. Cytoplasm. Note: Localized mainly in the nucleus with minor staining in the cytoplasm. Ref.9 Ref.34 Ref.37 Ref.43 Ref.53 Ref.61 Ref.63 Ref.70Isoform 8: Nucleus. Cytoplasm. Note: Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli. Ref.9 Ref.34 Ref.37 Ref.43 Ref.53 Ref.61 Ref.63 Ref.70Isoform 9: Cytoplasm Ref.9 Ref.34 Ref.37 Ref.43 Ref.53 Ref.61 Ref.63 Ref.70.

Tissue specificity: Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine. Ref.9

Induction: Up-regulated in response to DNA damage. Isoform 2 is not induced in tumor cells in response to stress. Ref.9 Ref.34

Domain: The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors. Ref.42 Ref.74

Post-translational modification: Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1

By similarity. Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP. Ref.28 Ref.29 Ref.30 Ref.34 Ref.39 Ref.44 Ref.45 Ref.49 Ref.50 Ref.53 Ref.59 Ref.63 Ref.65 Ref.73 Ref.77 Ref.78 Ref.80 Ref.81 Ref.84Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A. Ref.28 Ref.29 Ref.30 Ref.34 Ref.39 Ref.44 Ref.45 Ref.49 Ref.50 Ref.53 Ref.59 Ref.63 Ref.65 Ref.73 Ref.77 Ref.78 Ref.80 Ref.81 Ref.84May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line. Ref.32Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner. Ref.35 Ref.53 Ref.60 Ref.61 Ref.70 Ref.82 Ref.83 Ref.86 Ref.88 Ref.93Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation. Ref.62 Ref.67 Ref.69 Ref.76 Ref.79 Ref.89 Ref.91Sumoylated by SUMO1. Ref.33 Ref.43

Involvement in disease: Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.Defects in TP53 are a cause of esophageal cancer (ESCR) [

MIM:133239].Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [

MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (Ref.139 and Ref.142) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. Ref.34 Ref.118 Ref.119 Ref.120 Ref.121 Ref.122 Ref.141 Ref.143 Ref.148 Ref.149Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [

MIM:275355]; also known as squamous cell carcinoma of the head and neck.Defects in TP53 are a cause of lung cancer (LNCR) [

MIM:211980].Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [

MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood. Ref.152Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [

MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome. Ref.151

Sequence similarities: Belongs to the p53 family.
Product References and Citations for anti-p53 antibody
Sylvie Labrecque, et al. Analysis of the Anti-p53 Antibody Response in Cancer Patients (1993) Cancer Research 53, 3468-3471

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

Contact Us

Please fill out the form below and our representative will get back to you shortly.